Continuous Bioprocessing Market Size – By Product [Instruments (Chromatography Systems, Filtration Systems and Devices), Consumables], Scale of Operation (Commercial, R&D), Process (Downstream, Upstream), Application, End-user & Global Forecast 2024 – 2032

Continuous Bioprocessing Market Size

Continuous Bioprocessing Market was valued at USD 207.6 million in 2023 and is projected to grow at a CAGR of over 22.1% from 2024 to 2032. Factors such as the increasing demand for biopharmaceuticals, growing adoption of continuous bioprocessing among CMOs and CDMOs, and advancements in continuous bioprocessing technologies majorly contributes to the remarkable market growth. Also, emerging markets, particularly in Asia-Pacific, are witnessing increased adoption of continuous bioprocessing technologies to support the growing demand for biologics, thereby further boosting business development.
 

Continuous bioprocessing is a method used in biotechnology and biopharmaceutical manufacturing where the production process operates continuously rather than in batches. In traditional batch processing, materials are loaded into a vessel, processed for a set period, and then harvested before the vessel is cleaned and prepared for the next batch. In continuous bioprocessing, the materials flow continuously through the system, with product continuously harvested at the output.
 

Continuous Bioprocessing Market Trends

• Biopharmaceutical companies are increasingly adopting continuous manufacturing approaches to improve efficiency, reduce costs, and enhance product quality. Continuous bioprocessing offer advantages such as higher productivity, reduced footprint, and enhanced process control, driving its adoption across the industry.
   
• Furthermore, single-use technologies are becoming increasingly integrated into continuous bioprocessing workflows. Single-use bioreactors, filtration systems, and other disposable components offer flexibility, scalability, and reduced risk of cross-contamination, making them well-suited for continuous manufacturing operations. Owing to these advantages, the market is expected to witness remarkable growth in coming years.
   

However, implementing continuous bioprocessing systems requires significant upfront investment in equipment, facility modifications, and training, which can be a barrier for some companies, particularly startups and smaller manufacturers.
 

Continuous Bioprocessing Market Analysis

Based on product, the market is segmented into instruments and consumables. The instrument segment is further sub-segmented into chromatography systems, filtration systems and devices, bioreactors, and other instruments. Whereas the consumables segment is sub-segmented into cell culture media & buffers and reagents. Among the products, instruments segment dominated the global market with 65.7% of market share in 2023.
 

• The instruments segment held highest market share due to its indispensable role in enabling efficient, automated, and quality-assured biopharmaceutical manufacturing processes.
   
• Furthermore, technological advancements, increasing automation, regulatory requirements, and rising demand for biologics are key factors driving the instruments segment growth.
   

Based on scale of operation, the continuous bioprocessing market is classified into commercial and research & development. The commercial segment accounted for USD 146.0 million in 2023 and in anticipated to reach USD 833.5 million by 2032.
 

• The commercial segment benefits from the high demand for biopharmaceutical products, including monoclonal antibodies, vaccines, cell and gene therapies, and other biologics.
   
• Also, as the global population ages and the prevalence of chronic diseases increases, there is a growing need for advanced biopharmaceutical therapies, further driving expansion in the commercial segment.
   
• Additionally, continuous bioprocessing offers advantages such as higher productivity and enhanced process control, making it well-suited for large-scale commercial production compared to traditional batch processing methods.
   

Based on process, the continuous bioprocessing market is categorized into downstream bioprocess and upstream bioprocess. The downstream bioprocess is anticipated to grow at CAGR of over 20.2% through 2032.
 

• The growth of this segment is attributed to its critical role in achieving product quality, meeting regulatory requirements, and adding significant value to biopharmaceutical products. Also, with increasing demand for biologics and growing outsourcing trends, manufacturers prioritize efficient and robust purification processes to ensure product quality and safety, thereby enhancing segmental growth.
   
• Further, continuous innovations in downstream processing solutions enable biopharmaceutical companies to enhance process efficiency, productivity, and scalability, further driving market growth in this segment.

Based on applications, the continuous bioprocessing market is divided into monoclonal antibodies, vaccines, cell and gene therapy, and other applications. The monoclonal antibodies segment accounted to majority of market share and is projected to surpass USD 583.3 million by 2032.
 

• Monoclonal antibodies are one of the largest and fastest-growing segments of the biopharmaceutical market. They are widely used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. The high demand for mAbs drives significant investment in manufacturing technologies, including continuous bioprocessing.
   
• Furthermore, the established manufacturing processes, method intensification opportunities, regulatory support, and technological advancements supports the growth of this segment.
   

Based on end-user, the continuous bioprocessing market is classified as pharmaceutical and biotechnology companies, CMOs and CROs, and research and academic institutes. The pharmaceutical and biotechnology companies segment was valued at USD 118.6 million in 2023.
 

• Pharmaceutical and biotechnology companies dominate the market due to their extensive focus on developing biologic drugs, particularly monoclonal antibodies, which represent a substantial portion of the biopharmaceutical market.
   
• These companies invest heavily in research and development to innovate bioprocessing technologies, ensuring compliance with regulatory standards while maximizing operational efficiency.
   
• Their diverse portfolios of biologics, global market presence, regulatory expertise, and strategic collaborations further solidify their position as key drivers.

North America dominated the global continuous bioprocessing market and is expected to reach USD 438.2 million by 2032 with a CAGR of 20%.
 

• North America is home to many biopharmaceutical companies, including pharmaceutical giants. These companies lead in the development and commercialization of biologic drugs, driving the demand for continuous bioprocessing technologies to streamline manufacturing operations, enhance productivity, and ensure product quality.
   
• In addition, this region boasts of a robust ecosystem of research institutions, academic centers, and biotechnology clusters that foster innovation in bioprocessing technologies. North American companies and research organizations invest heavily in R&D to develop cutting-edge bioprocessing platforms, driving advancements in continuous bioprocessing and maintaining a competitive edge in the global market.
   

Continuous Bioprocessing Market Share

The continuous bioprocessing industry is dynamic and multifaceted, characterized by presence of a diverse array of players such as Thermo Fisher Scientific, Sartorius AG, and Merck KGaA. As the demand for biopharmaceuticals continues to grow and technology advances, competition in the market is expected to intensify, driving further innovation and market consolidation.
 

Continuous Bioprocessing Market Companies

Key players operating in the continuous bioprocessing industry include:

• 3M Company
• Bionet
• Danaher Corporation (Pall Corporation)
• Eppendorf SE
• FUJIFILM HOLDINGS CORPORATION
• Merck KGaA
• Repligen Corporation
• Sartorius AG
• Thermo Fisher Scientific Inc.
• WuXi Biologics
   

Continuous Bioprocessing Industry News

• In August 2023, Sartorius and Repligen Corporation introduced an integrated bioreactor system combining Biostat STR and XCell ATF technologies, aimed at enhancing upstream process intensification. The launch is expected to help the company to expand its product portfolio and revenue generated from its sales.
   
• In April 2018, Wuxi Biologics announced to invest USD 371.7 million for the construction of Ireland's largest biomanufacturing facility, employing single-use bioreactors. This strategic initiative helped the company to increased production capacity.
   

This continuous bioprocessing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
  • Chromatography systems
  • Filtration systems and devices
  • Bioreactors
  • Other instruments
• Consumables
  • Cell culture media & buffers
  • Reagents

Market, By Scale of Operation

• Commercial
• Research and development

Market, By Process

• Downstream bioprocess
• Upstream bioprocess

Market, By Application

• Monoclonal antibodies
• Vaccines
• Cell and gene therapy
• Other applications

Market, By End-user

• Pharmaceutical and biotechnology companies
• CMOs and CROs
• Research and academic institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa